Compare QFIN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QFIN | PHVS |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2018 | 2020 |
| Metric | QFIN | PHVS |
|---|---|---|
| Price | $12.33 | $27.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $32.37 | ★ $40.70 |
| AVG Volume (30 Days) | ★ 1.4M | 134.2K |
| Earning Date | 03-17-2026 | 05-12-2026 |
| Dividend Yield | ★ 12.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.60 | $11.51 |
| 52 Week High | $46.18 | $29.80 |
| Indicator | QFIN | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 28.63 | 52.71 |
| Support Level | N/A | $24.25 |
| Resistance Level | $14.63 | $28.06 |
| Average True Range (ATR) | 0.57 | 1.23 |
| MACD | -0.07 | 0.11 |
| Stochastic Oscillator | 0.00 | 69.23 |
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.